Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Relma-cel in moderate to severe active SLE
NCT06297408Phase 1Not yet recruiting
- Sponsor
- Shanghai Ming Ju Biotechnology
- Start
- Mar 2024
- Primary completion
- May 2025
- Modality
- Gene Editing, Gene Silencing, CAR-T Cells
01
Overview
Phase 1, randomised, open-label trial of relmacabtagene autoleucel in systemic lupus erythematosus (SLE) (2 arms), sponsored by Shanghai Ming Ju Biotechnology. Primary endpoints: Dose-Limiting Toxicity Rate at 6 months and Recommended Phase 2 Dose at 6 months. Planned start Mar 2024; status: not yet recruiting.
02
Drugs
relmacabtagene autoleucel
03
Conditions
systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on NCT06297408.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06297408.